Insider Transactions in Q1 2026 at Aurinia Pharmaceuticals Inc. (AUPH)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
Peter Greenleaf Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
113,169
-5.78%
|
$1,697,535
$15.95 P/Share
|
|
Jan 02
2026
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,384
+7.8%
|
-
|
|
Jan 02
2026
|
Joseph M Miller Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,161
-6.38%
|
$602,415
$15.95 P/Share
|
|
Jan 02
2026
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,038
+7.26%
|
-
|
|
Jan 02
2026
|
Matthew Maxwell Donley Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,787
-5.79%
|
$641,805
$15.95 P/Share
|
|
Jan 02
2026
|
Matthew Maxwell Donley Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,166
+6.87%
|
-
|
|
Jan 02
2026
|
Stephen P. Robertson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
40,385
-7.23%
|
$605,775
$15.95 P/Share
|
|
Jan 02
2026
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
48,558
+8.01%
|
-
|